Business Wire - King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of ALTACE® with Hydrochlorothiazide
BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company’s ALTACE([R]) (ramipril) diuretic fixed-dose combination product. The Company is continuing to evaluate the trial data and expects to present the findings in detail at an upcoming scientific conference.
About King Pharmaceuticals
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
10 Jobs That Pay $30 An Hour
Project Management: 24 Steps To Help You Master Any Project
13 Job Interview Mistakes To Avoid
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.
Forward-looking Statements
This release contains forward-looking statements which reflect management’s current views of future events and operations, including, but not limited to, statements pertaining to the expected presentation of Phase III results for the Company’s ALTACE([R])diuretic combination product at an upcoming scientific conference. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause actual results to differ materially from the forward-looking statements include dependence on King’s ability to present the Phase III results for its ALTACE([R])diuretic combination product as planned; and dependence on the final outcome of the Company’s review of the data. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the “Risk Factors” section and other sections of King’s Form 10-K for the year ended December 31, 2006, which is on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
